Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin

Svetlana Popadic; Branislav Lekic; Srdjan Tanasilovic; Martina Bosic; Milos Nikolic

doi:10.1111/dth.13152

Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin

Dermatol Ther. 2020 Jan;33(1):e13152. doi: 10.1111/dth.13152. Epub 2019 Nov 19.

Authors

Svetlana Popadic^{1

2}, Branislav Lekic¹, Srdjan Tanasilovic^{1

2}, Martina Bosic³, Milos Nikolic^{1

2}

Affiliations

¹ Clinic of Dermatovenereology, Clinical Center of Serbia, Belgrade, Serbia.
² Department of Dermatovenereology, School of Medicine, University of Belgrade, Belgrade, Serbia.
³ Institute of Pathology, School of Medicine, University of Belgrade, Belgrade, Serbia.

PMID: 31743946
DOI: 10.1111/dth.13152

Abstract

We present a patient with a 33-year history of poikilodermatous mycosis fungoides (MF) who subsequently developed CD30-positive large cell transformation. After 6 years of conventional MF treatment, side effects of therapy and/or concomitant diseases prevented the previously applied treatment modalities. The CD30-directed antibody-cytotoxic drug conjugate (brentuximab vedotin) was introduced and followed by quick and excellent therapeutic response.

Keywords: CD30-positive large cell transformation; brentuximab vedotin; mycosis fungoides.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents, Immunological / administration & dosage*
Brentuximab Vedotin / administration & dosage*
Humans
Ki-1 Antigen / immunology
Ki-1 Antigen / metabolism
Male
Mycosis Fungoides / drug therapy*
Skin Neoplasms / drug therapy*
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Ki-1 Antigen
Brentuximab Vedotin

Abstract

Publication types

MeSH terms

Substances

Grants and funding